158 related articles for article (PubMed ID: 31528172)
1. Role of FGFR3 in Urothelial Carcinoma.
Akanksha M; Sandhya S
Iran J Pathol; 2019; 14(2):148-155. PubMed ID: 31528172
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification.
Montes-Mojarro IA; Hassas S; Staehle S; Sander P; Harland N; Serna-Higuita LM; Bonzheim I; Bösmüller H; Stenzl A; Fend F
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897708
[TBL] [Abstract][Full Text] [Related]
3. Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder.
Maeng YH; Eun SY; Huh JS
Korean J Urol; 2010 Feb; 51(2):94-100. PubMed ID: 20414420
[TBL] [Abstract][Full Text] [Related]
4. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
5. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
6. Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer.
Poyet C; Hermanns T; Zhong Q; Drescher E; Eberli D; Burger M; Hofstaedter F; Hartmann A; Stöhr R; Zwarthoff EC; Sulser T; Wild PJ
Oncol Lett; 2015 Nov; 10(5):2753-2760. PubMed ID: 26722237
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions.
Matsumoto M; Ohtsuki Y; Ochii K; Seike Y; Iseda N; Sasaki T; Okada Y; Kurabayashi A; Furihata M
Oncol Rep; 2004 Nov; 12(5):967-71. PubMed ID: 15492779
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis.
Khalid S; Basulaiman BM; Emack J; Booth CM; Duran I; Robinson AG; Berman D; Smoragiewicz M; Amir E; Vera-Badillo FE
Eur Urol Open Sci; 2020 Oct; 21():61-68. PubMed ID: 34337469
[TBL] [Abstract][Full Text] [Related]
9. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin and FGFR3 are risk factors determining prognosis of patients with bladder urothelial carcinoma.
Jing W; Cao Y; Wang H; Qian D
Am J Transl Res; 2023; 15(2):1510-1516. PubMed ID: 36915751
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
Oliushina EM; Zavalishina LE; Alekseenok EY; Oskina NA; Andreeva YY; Kuznetsova OA; Filipenko ML; Frank GA
Arkh Patol; 2023; 85(2):5-12. PubMed ID: 37053347
[TBL] [Abstract][Full Text] [Related]
12. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
Guancial EA; Werner L; Bellmunt J; Bamias A; Choueiri TK; Ross R; Schutz FA; Park RS; O'Brien RJ; Hirsch MS; Barletta JA; Berman DM; Lis R; Loda M; Stack EC; Garraway LA; Riester M; Michor F; Kantoff PW; Rosenberg JE
Cancer Med; 2014 Aug; 3(4):835-44. PubMed ID: 24846059
[TBL] [Abstract][Full Text] [Related]
13. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
[TBL] [Abstract][Full Text] [Related]
14. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
15. Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
Shigeta K; Matsumoto K; Tanaka N; Mikami S; Kosaka T; Yasumizu Y; Takeda T; Mizuno R; Kikuchi E; Oya M
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563543
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
[TBL] [Abstract][Full Text] [Related]
17. Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy.
Ahn B; Kim D; Park KJ; Park JM; Yoon SY; Hong B; Cho YM; Kim D
Cancer Res Treat; 2023 Dec; ():. PubMed ID: 38147818
[TBL] [Abstract][Full Text] [Related]
18. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
20. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
